- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Tracheal and airway disorders
- Cancer Immunotherapy and Biomarkers
- Pleural and Pulmonary Diseases
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Myasthenia Gravis and Thymoma
- Medical Imaging and Pathology Studies
- Esophageal Cancer Research and Treatment
- Pituitary Gland Disorders and Treatments
- Cancer Genomics and Diagnostics
- Cardiac Arrhythmias and Treatments
- Venous Thromboembolism Diagnosis and Management
- PI3K/AKT/mTOR signaling in cancer
- Head and Neck Cancer Studies
- Cystic Fibrosis Research Advances
- Muscle and Compartmental Disorders
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Cancer Research and Treatments
- Tuberculosis Research and Epidemiology
Queen Mary University of London
2024
AstraZeneca (Japan)
2019-2022
Osaka Prefectural Medical Center
2015-2016
National Cancer Center Hospital East
2015
Kyoto Medical Center
2014
387 Background: This Phase 1 study (NCT01938612) evaluated D (anti-PD-L1 mAb) and T (anti-CTLA-4 in Asian pts, whom optimal dosing of is undetermined. No dose-limiting toxicities were observed, durable responses seen a dose escalation phase evaluating various doses regimens Japanese pts (Iguchi, ASCO 2015). The was subsequently expanded to larger cohorts with advanced solid tumors including BTC. Methods: Two selected for the expansion phase: monotherapy (10 mg/kg q2w) D+T (D 20 + 1.0 q4w)....
Agents targeting the programmed cell death-1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this I study evaluated safety, tolerability, and antitumor durvalumab monotherapy, plus tremelimumab (an anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody) combination therapy, in patients from Asia with biliary tract cancer (BTC), esophageal squamous carcinoma (ESCC), or head neck (HNSCC).Patients advanced BTC, ESCC,...
Diagnostic bronchoscopy has been considered as a safe and effective procedure. Endobronchial ultrasound with guide sheath (EBUS-GS) for the diagnosis of peripheral pulmonary lesions (PPLs) is becoming common procedure, but reports about its safety are missing.The aim this study was to evaluate profile EBUS-GS PPLs.All patients PPLs who underwent between September 2012 August 2014 at National Cancer Center Hospital were included. Postprocedural complications durability devices retrospectively...
Background The 2016 National Institute for Health and Care Excellence guidelines recommended the tuberculin skin test (TST), at a 5-mm induration size cut-off, diagnosis of latent tuberculosis infection (LTBI) among adult close contacts active (TB) cases. This study analysed well characterised cohort in London assess cost-effectiveness LTBI screening strategies with combinations TST interferon-gamma release assays (IGRAs) decision-analytic model. Methods Close pulmonary TB cases who were...
Endobronchial ultrasound with a guide sheath (EBUS-GS) has resulted to better diagnostic outcome for peripheral pulmonary lesions (PPLs), although the yield is not satisfactory that cannot be located by EBUS. We aimed evaluate whether addition of new technique, transbronchial needle aspiration through (GS-TBNA), can increase these cases.This was retrospective review cases were EBUS during EBUS-GS PPL diagnosis. From September 2012 August 2014, 67 PPLs had 'invisible' location prior sampling....
ObjectiveEndobronchial ultrasound with a guide sheath has been widely used diagnostic procedure for peripheral pulmonary lesions. After sequential sampling the usual devices, small portions of collected specimen remain in and these can potentially contribute to diagnosis. We assessed value each histological cytological sample, especially flush, malignancies.
Radial endobronchial ultrasound with a guide sheath (EBUS-GS) has improved the diagnostic outcomes of peripheral lung lesions. However, to our knowledge, reports on use EBUS-GS for diagnosis cavitary lesions are unavailable. Therefore, this study aimed assess effectiveness and safety (PCLLs).This was single-institution retrospective review PCLLs examined by using between July 2013 October 2015. The results different samples, including cytologic, histopathologic, microbiologic were analysed...
Blockade of programmed cell death ligand‐1 with durvalumab has shown efficacy and safety in large, international studies patients advanced solid tumors. A phase 1, non‐randomized, open‐label multicenter study was initiated to evaluate a Japanese population. The first part this used standard 3 + dose‐escalation design determine the optimal dosing schedule durvalumab. Primary objective evaluation tolerability monotherapy. Secondary objectives were maximum tolerated dose ( MTD ),...
Abstract Background In the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved OS versus EP alone in patients with extensive-stage (ES)-SCLC (HR 0.73 [95% CI 0.59–0.91; p = 0.0047]). Here we report results for a preplanned subgroup analysis of recruited Japan. Methods Treatment-naïve ES-SCLC received either 4 cycles 1500 mg q3w followed by maintenance q4w until disease progression up to 6 q3w. The primary endpoint...
Pulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because of its nonspecific signs symptoms. PE also an important potential risk osimertinib treatment, however, clinical courses regarding retreatment after osimertinib-induced acute pulmonary remain unclear. We described a 77-year-old woman with postoperative recurrent lung adenocarcinoma who developed PE. She received apixaban was later successfully retreated osimertinib. This case suggests that may treatment...
Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome MET-based resistance to EGFR-TKIs. To investigate the safety tolerability of savolitinib in Japanese patients advanced solid malignancies. In Part C phase Ib, multi-arm, open-label, multicenter TATTON study, two cohorts adult were evaluated across six study...
Abstract: Chronic lymphocytic leukemia (CLL) is a monoclonal B-cell lymphoproliferative disease with high annual incidence in Western countries. As receptor (BCR) signaling and intrinsic apoptotic resistance play critical roles the development survival of CLL cells, therapeutic approaches targeting these pathways have been extensively investigated to tackle this incurable disease. Over last decade, several Phase 3 trials confirmed superior efficacy covalent Bruton tyrosine kinase inhibitors...
Abstract A 68‐year‐old woman with interstitial lung disease related to dermatomyositis and systemic scleroderma was admitted our hospital fever dyspnoea. Although the reduced after antibiotic therapy, a left pneumothorax suddenly occurred on day 27 admission. continuous air leak persisted despite chest drainage three tubes repeated pleurodesis. Chest computed tomography (CT) images showed cavitary lesion pinhole in upper division, which suspected be affected leak. Virtual bronchoscopic...
Long-term oxygen therapy (LTOT) is sometimes prescribed for patients with advanced lung cancer who are potential candidates chemotherapy. The aim of this study was to assess the usefulness chemotherapy disease require LTOT.The medical records 40 received LTOT while undergoing systemic at our institution between January 2009 and December 2014 were retrospectively reviewed. Chemotherapy consisted cytotoxic or molecular-targeted agents.Twenty-four had adenocarcinoma, 6 squamous cell carcinoma,...
A 72-year-old man with salivary gland cancer and multiple pulmonary metastases suffering from intractable pneumothorax was transferred to our institution; he inoperable because of a low function. chest tube had been placed more than month prior this admission. digital drainage system used for 24-h monitoring air leaks (Thopaz®). Using the Thopaz® system, we performed endoscopic bronchial occlusion using an endobronchial Watanabe spigot (EWS) reduce leaks. Finally, ceased, removed five days...
Abstract Exon18 mutations are detected in 3.6% of epidermal growth factor receptor mutations. Exon 18 as driver have higher sensitivities vitro to second‐generation (G)‐tyrosine kinase inhibitors (TKIs) than first G‐ and third G‐TKIs at clinically relevant doses. In clinical trial, moderate but insufficient efficacy, afatinib was more active uncommon Here, we present a case woman who initially prescribed erlotinib for lung adenocarcinoma with an exon18 mutation. She developed leptomeningeal...
Abstract Background The primary objective of this phase I, open-label trial was to assess safety and tolerability tremelimumab monotherapy combination therapy with durvalumab in Japanese patients advanced cancer. Tremelimumab is a fully human monoclonal antibody against CTLA-4 clinical trials; PD-L1 for the treatment bladder lung Methods In part 1, 3 or 10 mg/kg given every 4 weeks (Q4W) 6 doses, thereafter 12 until discontinuation (n = 8); subsequently Q4W doses/Q12W administered 41...
We report a case of life-threatening haemoptysis after administration dabigatran in patient with bronchiectasis. A 72-year-old woman had received at dose 110 mg twice daily for chronic atrial fibrillation. She was admitted to our hospital cerebral infarction few days self-interruption dabigatran. After the diagnosis infarction, restarted. Seven later, she suffered acute-onset massive and required mechanical ventilation. Dabigatran treatment discontinued, bronchial artery embolisation (BAE)...
An 87-year-old man with postoperative recurrent lung adenocarcinoma was treated gefitinib. At the beginning of treatment, surgically resected archived tumor tissue revealed a deletion in exon 19 EGFR gene, but no ALK gene rearrangement. After gefitinib treatment for 9 months, disease progressed. Bronchoscopic rebiopsy used to evaluate resistance mechanisms, and wild-type genes newly emerged Treatment switched alectinib partial response achieved within 4 weeks. This is rare case heterochronic...
A 54-year-old man presented to our emergency department with fever and dyspnoea. He required vigorous haemodynamic support mechanical ventilation for hypotensive distributive shock hypoalbuminaemia, haemoconcentration, rhabdomyolysis acute renal failure, consistent idiopathic systemic capillary leak syndrome. Left lung consolidation hypoxaemia were observed 6 days after admission. Sputum smear revealed the presence of angled branching hyphae, a diagnosis invasive pulmonary aspergillosis....
<b>Objective:</b> EBUS elastography (E-ELT) is a new technique for describing the stiffness of tissue during EBUS-TBNA. This study was to evaluate utility E-ELT type classification thoracic lymph nodes (LNs). <b>Methods:</b> Seventy-five LNs were evaluated. patterns classified as follows: Type 1, predominantly non-blue; 2, part blue, 3, blue. The compared with pathologic results. <b>Results:</b> that 1 on benign in 24/24 (100%); 2 LNs, 6/14 (46.9%) and 8/14 (57.1%) malignant; 3 2/37 (5.4%)...
A prolonged air leak caused by pulmonary tuberculosis is difficult to treat, and little known about optimal treatment strategies. We herein report the case of a 60-year-old man who demonstrated tuberculous empyema with fistula. An from cavity in his left upper lobe persisted for approximately 4 months; surgical repair could not be performed due poor physical status undernourishment. However, was successfully treated endobronchial occlusion using two silicone spigots B3b B4, without any...
<b>Objective:</b> Diagnostic bronchoscopy has been considered as one of the safe and effective procedures. Endobronchial ultrasound with a guide sheath (EBUS-GS) for diagnosis peripheral pulmonary lesion (PPL) is becoming common procedure but there no report about its safety. The aim this study was to evaluate safety profile EBUS-GS PPLs. <b>Methods:</b> All patients PPLs who underwent between September 2012 August 2014 at National Cancer Center Hospital were included. Post-procedural...